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SUMMARY
Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), is recognized as a global health emergency as
promoted by the World Health Organization. Over 1 million deaths per year, along with the emergence of multi- and
extensively-drug resistant strains of Mtb, have triggered intensive research into the pathogenicity and biochemistry of
this microorganism, guiding the development of anti-TB chemotherapeutic agents. The essential mycobacterial cell
wall, sharing some common features with all bacteria, represents an apparent ‘Achilles heel’ that has been targeted by
TB chemotherapy since the advent of TB treatment. This complex structure composed of three distinct layers, peptido-
glycan, arabinogalactan and mycolic acids, is vital in supporting cell growth, virulence and providing a barrier to antibio-
tics. The fundamental nature of cell wall synthesis and assembly has rendered the mycobacterial cell wall as the most
widely exploited target of anti-TB drugs. This review provides an overview of the biosynthesis of the prominent cell
wall components, highlighting the inhibitory mechanisms of existing clinical drugs and illustrating the potential of
other unexploited enzymes as future drug targets.
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INTRODUCTION
Mycobacterium tuberculosis (Mtb), the causative
agent of tuberculosis (TB), is regarded as the
world’s most successful pathogen (Hingley-Wilson
et al. 2003). Responsible for an estimated 1·4
million deaths and 10·4 million new cases of TB,
including 480 000 new cases of multi-drug resistant
(MDR)-TB in 2015 (World Health Organization,
2016), Mtb remains a global health emergency as
declared by the World Health Organization
(WHO) (World Health Organization, 2014). New
chemotherapeutic agents to complement or replace
existing front-line treatment regimens are urgently
required to reduce treatment time (currently
6-month course) and to combat the increasing
threat by this microorganism.
The distinguishing feature of mycobacteria, the
complex cell wall, is a well-recognized drug target.
The cell wall is common to all bacteria, both Gram-
positive and Gram-negative, but can have vast diﬀer-
ences in terms of the biochemical and structural
features. Over the past decade, extensive research
into cell wall assembly, aided by whole-genome
sequencing, has led to an increased understanding of
mycobacterial cell wall biosynthesis. This has pro-
moted further exploration into the discovery and
development of chemotherapeutic agents (from an
enzymatic and phenotypic perspective) directed
against the synthesis of this unique macromolecule
structure inMtb. TheMtb cell envelope is an expan-
sive structure and is summarized in Fig. 1. The inner
membrane phospholipid bilayer contains glycolipids
that extend into the periplasmic space. The essential
core cell wall structure is composed of three main
components: a cross-linked polymer of peptidogly-
can, a highly branched arabinogalactan polysacchar-
ide, and long-chain mycolic acids. Intercalated into
the mycolate layer are solvent-extractable lipids
including non-covalently linked glycophospholipids
and inert waxes, forming the outer membrane. The
capsule forms the outermost layer and is mainly com-
posed of proteins and polysaccharides. The lipid- and
carbohydrate-rich layers of the cell wall serve not only
as a permeability barrier, providing protection against
hydrophilic compounds, but also are critical in patho-
genesis and survival. It is these traits that make the
biosynthesis and assembly of the cell wall components
attractive drug targets. This review focuses on the
synthesis of the key cell wall components, highlight-
ing previously validated targets and the ongoing
drug discovery eﬀorts to inhibit other essential
enzymes in mycobacterial cell wall biosynthesis.
PEPTIDOGLYCAN
Peptidoglycan is a major component of the cell wall
of both Gram-positive and Gram-negative bacteria
(Vollmer et al. 2008). It is a polymer of alternating
N-acetylglucosamine and N-acetylmuramic acid
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residues via β(1→ 4) linkages with side chains of
amino acids cross-linked by transpeptide bridges
(Brennan and Nikaido, 1995). Mycobacterial pep-
tidoglycan has a number of unique features that
diversiﬁes the cell wall from the typical structure
including N-glycolyl- and N-acetyl-muramic acid
residues (Mahapatra et al. 2005a), amidation of the
carboxylic acids in the peptide stems (Mahapatra
et al. 2005b) and additional glycine or serine residues
(Vollmer et al. 2008). The function of peptidoglycan
is not only to provide shape and rigidity, but it is
responsible for counteracting turgor pressure and
hence it is essential for growth and survival
(Vollmer et al. 2008). Peptidoglycan is unique to
bacterial cells, and it is this property that has led to
numerous enzymes involved in its synthesis to be
targeted by potent antibiotics, with others represent-
ing attractive targets in the development of future
antibiotics.
PEPTIDOGLYCAN BIOSYNTHESIS
The biosynthesis of peptidoglycan is summarized in
Fig. 2. The ﬁrst committed step is the generation of
uridine diphosphate-N-acetylglucosamine (UDP-
GlcNAc). This is catalysed by the acetyltransferase
and uridyltransferase activities of GlmU (Zhang
et al. 2009), where ﬁrst the acetyl group from
acetyl-CoA is transferred to glucosamine-1-phosphate
(GlcN-1-P) to produce N-acetylglucosamine-1-
phosphate (GlcNAc-1-P). Secondly, uridine-5′-mono-
phosphate from UTP is transferred to GlcNAc-1-P to
yield UDP-GlcNAc (Zhang et al. 2009). The abun-
dance of GlcNAc-1-P in eukaryotes (Mio et al. 1998)
and the functional similarity of the GlmU uridyltrans-
ferase with human enzymes (Peneﬀ et al. 2001) makes
this domain an unsuitable drug target (Rani andKhan,
2016). However, the absence of GlcN-1-P from
humansmakes the acetyltransferase domain a potential
target (Mio et al. 1998). Eﬀorts to identify inhibitors of
this domain are underway (Tran et al. 2013). A sub-
strate analogue of GlcN-1-P has been designed and
exhibits inhibitory eﬀect against GlmU, providing a
candidate for further optimization (Li et al. 2011).
Thenext step involves thegenerationof theUDP-N-
acetylmuramic acid (UDP-MurNAc)-pentapeptide,
which is synthesized in a sequential pathway catalysed
by the Mur ligases A–F (Barreteau et al. 2008),
whereby most of the Mtb genes have been found
through homology. MurA, a UDP-N-acetylglucosa-
mine 1-carboxyvinyltransferase, and MurB, a UDP-
N-acetylenolpyruvoylglucosamine reductase, are
involved in generating UDP-MurNAc from UDP-
GlcNAc, by ﬁrst the addition of the enoylpyruvyl
moiety of PEP, followed by reduction to a lactoyl
ether moiety via NADPH. At this point, NamH, a
Fig. 1. The mycobacterial cell wall. A schematic representation of the mycobacterial cell wall, depicting the prominent
features, including the glycolipids (PIMs, phosphatidyl-myo-inositol mannosides; LM, lipomannan; LAM,
lipoarabinomannan; ManLAM, mannosylated lipoarabinomannan), peptidoglycan, arabinogalactan and mycolic acids.
Intercalated into the mycolate layer are the acyl lipids (including TMM, trehalose monomycolate; TDM, trehalose
dimycolate; DAT, diacyltrehalose; PAT, polyacyltrehalose; PDIM, phthiocerol dimycocerosate; SGL, sulfoglycolipid).
The capsular material is not illustrated.
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UDP-N-acetylmuramic acid hydroxylase, hydroxy-
lates UDP-MurNAc to UDP-N-glycolylmuramic
acid (UDP-MurNGlyc), providing both types of
UDP-muramyl substrates; Mtb cell walls are domi-
nated by the latter (Mahapatra et al. 2005a). This struc-
tural modiﬁcation is unique to mycobacteria (and
closely related genera) and is considered to increase
the intrinsic strength of peptidoglycan, by potentially
alleviating susceptibility to lysozyme and providing
sites for additional hydrogen bonding (Raymond et al.
2005). Inhibitors of Mtb MurA and MurB are yet to
be discovered. Whilst the natural product, broad spec-
trum antibiotic, fosfomycin, targets Gram-negative
MurA, the critical residue for inhibition is absent in
Mtb, providing intrinsic resistance against this anti-
biotic (Kim et al. 1996). Consequently, an inhibitor
with a new mode of action is required to target Mtb
MurA. A limited number of inhibitors have been
reported against MurB. Molecular dynamics and
docking studies of existingMurB inhibitors (3,5-dioxo-
pyrazolidine derivatives) onto theMtbMurB structure
reveal the potential potent activity of these compounds,
which can be used to guide future structure-based drug
design (Kumar et al. 2011). Inhibitors of NamH have
not been documented; namH is not essential in
Mycobacterium smegmatis, and therefore is not condu-
sive to a characteristic target property. However, gene
deletion results in a strain hypersusceptible to β-
lactamantibiotics and lysozymeandtherefore inhibitors
of NamH could potentiate the eﬀect of β-lactams
(Raymond et al. 2005).
The pentapeptide chain is incorporated onto the
UDP-MurNAc/Glyc substrates by the successive
addition of amino acid residues L-alanine, D-isogluta-
mate, meso-diaminopimelate (m-DAP) and D-alanyl-
D-alanine [generated by the D-Ala: D-Ala ligase
(Ddl)] by the ATP-dependent Mur ligases C-F
respectively (Munshi et al. 2013). This results in
the muramyl-pentapeptide product, UDP-MurNAc/
Glyc-L-Ala-D-isoGlu-m-DAP-D-Ala-D-Ala, also
known as Park’s nucleotide (Kurosu et al. 2007).
Despite the diﬀerent amino acid speciﬁcities, the
four ligases share common properties: the reaction
mechanism; six invariant ‘Mur’ residues; an ATP-
binding consensus; three-dimensional structural
domains (Barreteau et al. 2008). Due to these similar-
ities, it is plausible that a single inhibitor could target
more than one Mur ligase and such inhibitors have
been reported in the literature (Tomasic et al. 2010).
Numerous small molecule inhibitors of the Mur
Fig. 2. Inhibitors targeting peptidoglycan biosynthesis. The roles of the key enzymes involved in peptidoglycan
biosynthesis are illustrated. Reported inhibitors are shown in red.
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ligases have been discovered and are the subject of an
extensive review (Hrast et al. 2014). In most cases, the
inhibitors were identiﬁed from high-throughput
screening (HTS) campaigns of compound libraries
employing in vitro kinetic assays. These types of in
vitro screening methods are limited in use against
Mtb Mur ligases given that only MurC and MurE
have been biochemically characterized (Mahapatra
et al. 2000; Li et al. 2011). This dictates the next
rational step towards the target-based discovery of
Mur ligase inhibitors. Ddl is the target of D-cycloser-
ine (Bruning et al. 2011), a second-line drug used in
the treatment of TB, and is at the cornerstone of treat-
ment forMDR and extensively drug resistant (XDR)-
TB. D-cycloserine acts as a structural analogue of D-
Ala, inhibiting the binding of either D-Ala to Ddl
(Prosser and de Carvalho, 2013a, b).
The ﬁrst membrane-anchored peptidoglycan pre-
cursor is generated by the translocation of Park’s
nucleotide to decaprenyl phosphate (C50-P), cata-
lysed by MurX (also known as MraY), forming
Lipid I (Kurosu et al. 2007). There are a number
of nucleoside-based complex natural products that
inhibit MurX, including muraymycin, liposidomy-
cin, caprazamycin and capuramycin (Dini, 2005).
Capuramycin and derivatives exhibit killing in
vitro and in vivo and more signiﬁcantly, analogues
of capuramycin have been shown to kill non-
replicatingMtb, a feature not common to the major-
ity of cell wall biosynthesis inhibitors (Koga et al.
2004; Reddy et al. 2008; Nikonenko et al. 2009;
Siricilla et al. 2015). Signiﬁcantly, the analogue
SQ641 is in preclinical development (http://www.
newtbdrugs.org).
The ﬁnal intracellular step of peptidoglycan syn-
thesis is performed by the glycosyltransferase,
MurG. A β(1→ 4) linkage between GlcNAc (from
UDP-GlcNAc) and MurNAc/Glyc of Lipid I is
formed, leading to the generation of Lipid II, the
monomeric building block of peptidoglycan
(Mengin-Lecreulx et al. 1991). A library of transi-
tion state mimics have been designed for
Escherichia coli MurG, and tested against Mtb
MurG with partial success, one being the ﬁrst
inhibitor identiﬁed against the Mtb enzyme
(Trunkﬁeld et al. 2010).
The enzyme catalysing the translocation of Lipid
II across the plasma membrane has been the subject
of much debate. To date, there is evidence for two
diﬀerent enzymes with ‘ﬂippase’ activity: MurJ and
FtsW (Ruiz, 2008, 2015; Mohammadi et al. 2011,
2014; Sham et al. 2014). Further biochemical charac-
terization is required to conﬁrm the identiﬁcation of
the ‘ﬂippase’. Inhibitors against this enzyme would
be expected to exhibit broad-spectrum activity, tar-
geting a vital activity in all bacteria.
Following translocation across the plasma mem-
brane, Lipid II is polymerized by the monofunc-
tional and bifunctional Penicillin-binding proteins
(PBPs) (Sauvage et al. 2008). Bifunctional PBPs
(PonA1/PBP1 and PonA2/PBP2) possess transgly-
cosylase and transpeptidase domains. The former
domain is responsible for linking the disaccharide
building blocks of Lipid II to the pre-existing
glycan chains (with the concomitant release of deca-
prenyl pyrophosphate), whereas the latter domain
catalyses the formation of the classical (3→ 4) cross-
links, between m-DAP and D-Ala of the adjacent
pentapeptide chains, with the cleavage of the terminal
D-Ala. D,D-transpeptidation and D,D-carboxypep-
tidation is performed by the monofunctional PBPs,
both resulting in the cleavage of the terminal D-Ala
of the peptide stem (Goﬃn and Ghuysen, 2002).
Only 20% of the cross-links in Mtb peptidoglycan
are (3→ 4) (Kumar et al. 2012). The majority are
(3→ 3) links between two tetrapeptide stems, with
the release of the fourth position D-Ala (Lavollay
et al. 2008). This reaction is catalysed by the L,D-
transpeptidases, with D,D-carboxypeptidation as a
prerequisite activity. The L,D-transpeptidases are
structurally unrelated to PBPs, with diﬀerent active
site residues (cysteine and serine, respectively)
(Mainardi et al. 2005; Biarrotte-Sorin et al. 2006).
The β-lactam antibiotics have been used in the treat-
ment of bacterial infections for nearly a century, and
gave rise to the discovery of their target, the PBPs.
The L,D-transpeptidases are resistant to most β-
lactam antibiotics, except the carbapenems (Dubee
et al. 2012). Until recently, β-lactams were not con-
sidered for use in the treatment of TB, due to the
expression of a broad-spectrum β-lactamase, BlaC.
However, it has been shown that BlaC is irreversibly
inactivated by clavulanic acid, yet hydrolyses carba-
penems at a low rate (Hugonnet et al. 2009).
Combined treatment of the β-lactam with the β-lacta-
mase inhibitor has been shown to be bactericidal
against both replicating and non-replicating forms
of Mtb, and combinations are now being explored
in clinical trials (Hugonnet et al. 2009; Rullas et al.
2015). A well-documented inhibitor of the transgly-
cosylase of PBPs, moenomycin (van Heijenoort
et al. 1987), a natural product glycolipid, is yet to
have proven eﬃcacy againstMtb.
The inhibitors discussed thus far directly target the
enzymes involved in peptidoglycan biosynthesis.
There are, however, other antibiotics that act on the
peptidoglycan precursors. For example, the glyco-
peptides, vancomycin and teicoplanin, bind to the
D-Ala-D-Ala terminus of the pentapeptide stem,
preventing polymerization reactions (Reynolds,
1989). Members of the lantibiotic family of antibio-
tics, such as nisin, interact with the pyrophosphate
moiety of Lipid II, forming a pore in the cytoplasmic
membrane, but also inhibiting peptidoglycan biosyn-
thesis (Wiedemann et al. 2001). The lipoglycodepsi-
peptide ramoplanin inhibits the action of MurG by
binding to Lipid I. Ramoplanin also binds to Lipid
II, preventing its polymerization (Lo et al. 2000).
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ARABINOGALACTAN
The major cell wall polysaccharide, arabinogalactan
(Fig. 1), as the name suggests, is composed of galact-
ose and arabinose sugar residues, in the furanose (f)
ring form (Galf) (McNeil et al. 1987).
Arabinogalactan is attached to peptidoglycan via a
single linker unit (McNeil et al. 1990). The galactan
component is a linear chain of approximately 30
alternating 5- and 6-linked β-D-Galf residues
(Daﬀe et al. 1990). Three highly branched arabinan
chains, consisting of approximately 30 Araf residues,
are attached to the galactan chain (Besra et al. 1995).
The non-reducing termini of the arabinan chains act
as an attachment site for mycolic acids, succinyl and
galactosamine (D-GalN) moieties (Draper et al.
1997; Bhamidi et al. 2008).
ARABINOGALACTAN BIOSYNTHESIS
Arabinogalactan biosynthesis is illustrated in Fig. 3.
The ﬁrst committed step begins in the cytoplasm
and proceeds by the formation of the linker unit con-
necting peptidoglycan to arabinogalactan, which is
initiated by WecA, a GlcNAc-1-P transferase (Jin
et al. 2010). This enzyme catalyses the transfer of
GlcNAc-1-P to C50-P. WbbL, a rhamnosyltransfer-
ase catalyses the transfer of L-rhamnose (L-Rha)
from dTDP-L-Rha to position 3 of C50-P-P-
GlcNAc to form C50-P-P-GlcNAc-L-Rha, com-
pleting the linker unit (McNeil et al. 1990; Mills
et al. 2004). WecA has been identiﬁed as the target
of caprazamycin derivatives, such as CPZEN-45,
with the original nucleoside antibiotic shown to
target MraY (Ishizaki et al. 2013). Recently, a ﬂuor-
escence-based assay for WecA activity has been
developed and used to screen compound libraries
with some success (Mitachi et al. 2016). Inhibitors
targeting WbbL have yet to be identiﬁed. This
essential enzyme, present in all mycobacteria, is
recognized as a promising target and eﬀorts are
underway to characterize the enzyme via the estab-
lishment of a microtiter plate-based assay for its
activity, which could be exploited in inhibitor
library screening (Grzegorzewicz et al. 2008).
The linker unit provides an attachment point for
the polymerization of the galactan chain. This
process also occurs in the cytoplasm. The bifunc-
tional galactofuranosyltransferases (GlfT1 and
GlfT2) (Alderwick et al. 2008) are responsible for
the synthesis of the linear galactan chain. Initially,
GlfT1 transfers Galf from UDP-Galf to the C-4
position of L-Rha, and then adds a second Galf
residue to the C-5 position of the primary Galf, gen-
erating C50-P-P-GlcNAc-L-Rha-Galf2 (Mikusova
et al. 2006; Alderwick et al. 2008; Belanova et al.
2008). GlfT2 sequentially transfers Galf residues
to the growing galactan chain with alternating β
(1→ 5) and β(1→ 6) glycosidic linkages (Kremer
et al. 2001a; Rose et al. 2006). The galactan chains
contain ∼30 Galf residues in vivo, forming C50-P-
P-GlcNAc-L-Rha-Galf30 (Daﬀe et al. 1990), but
the chain length determination mechanism is yet to
be fully understood. GlfT1 and GlfT2 are suitable
targets, as rationalized by an in silico target identiﬁ-
cation program (Raman et al. 2008). UDP-Galf deri-
vatives, with modiﬁcations to the C-5 and C-6
positions have been investigated as suitable inhibi-
tors of these enzymes, whereby they cause premature
galactan chain termination (Peltier et al. 2010).
The remainder of arabinogalactan synthesis occurs
on the outside of the cell. Although the transport
mechanism of this cell wall polysaccharide is not
fully understood, Rv3781 and Rv3783, encoding an
ABC transporter, are potential ‘ﬂippase’ candidates
(Dianiskova et al. 2011). Araf residues are transferred
directly onto C50-P-P-GlcNAc-L-Rha-Galf30 from
the lipid donor decaprenylphosphoryl-D-arabinose
(DPA) (Wolucka et al. 1994). DPA is synthesized
through a series of cytoplasmic steps, and originates
exclusively from phospho-α-D-ribosyl-1-pyrophos-
phate (pRpp), prior to reorientation to the extracellular
Fig. 3. Inhibitors targeting arabinogalactan biosynthesis. The current understanding of the roles of enzymes involved in
arabinogalactan biosynthesis. Reported inhibitors are shown in red.
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face of the plasma membrane. The pRpp synthetase,
PrsA, catalyses the transfer of pyrophosphate from
ATP to C-1 of ribose-5-phosphate, forming pRpp
(Alderwick et al. 2011b). A decaprenyl moiety is
added, catalysed by UbiA (decaprenol-1-phosphate
5-phosphoribosyltransferase), forming decaprenol-1-
monophosphate 5-phosphoribose (Alderwick et al.
2005; Huang et al. 2005, 2008). Rv3807c encodes a
putative phospholipid phosphatase, which catalyses
C-5 dephosphorylation, generating decaprenol-1-
phosphoribose (DPR) (Jiang et al. 2011). Finally,
DPA is generated by an epimerization reaction of the
ribose C-2 hydroxyl, catalysed by a two-step oxida-
tion/reduction activity of the decaprenylphosphori-
bose-2′-epimerase consisting of subunits DprE1 and
DprE2 (Mikusova et al. 2005).
The DPA synthetic pathway is a validated drug
target. The nitro-benzothiazinones (BTZs) and the
structurally related dinitrobenzamides target
DprE1 and are eﬀective against MDR and XDR
strains of Mtb with low toxicity (Christophe et al.
2009; Batt et al. 2012; Makarov et al. 2014, 2015).
The success of these compounds has led to the
study of the other enzymes as potential drug
targets. Conditional knockdown mutants of dprE1,
dprE2, ubiA, prsA and Rv3807c have proven the
essentiality of all except Rv3807c, and a target-
based whole-cell screen has been developed using
these strains of reduced expression levels to identify
enzyme-speciﬁc inhibitors. Inhibitors targeting a
particular enzyme cause increased sensitivity and
this was conﬁrmed with BTZ and KRT2029 target-
ing DprE1 and UbiA, respectively, and can be the
subject of future medicinal chemistry eﬀorts (Kolly
et al. 2014).
The mechanism of DPA reorientation into the
periplasm is unknown. The ‘ﬂippase’ was recently
considered to be Rv3789, but there is evidence that
this protein plays a diﬀerent role: to act as an
anchor protein to recruit AftA (Kolly et al. 2015).
AftA is the ﬁrst arabinofuranosyltransferase
(AraT), of a predicted six, to commence the addition
of arabinose from DPA onto the galactan chain
(Alderwick et al. 2006). AftA transfers a single
Araf residue onto C-5 of β(1→ 6) Galf residues 8,
10 and 12 of C50-P-P-GlcNAc-L-Rha-Galf30
(Alderwick et al. 2005). EmbA and EmbB, so
called because their discovery was based on the
mode of action elucidation of ethambutol (EMB),
catalyse the addition of further α(1→ 5) Araf poly-
merization (Alderwick et al. 2005). AftC introduces
α(1→ 3) branching (Birch et al. 2008), with AftD
having an equivalent role (Skovierova et al. 2009).
The structure terminates in a well-deﬁned hexa-
arabinofuranosyl (Araf6) structural motif: [β-D-Araf-
(1→ 2)-α-D-Araf]2-3,5-α-D-Araf-(1→ 5)-α-D-Araf.
This motif is generated by EmbA, EmbB, AftC, AftD
and AftB (Escuyer et al. 2001; Alderwick et al. 2005;
Birch et al. 2008, 2010; Skovierova et al. 2009). AftB
catalyses the transfer of the terminal β(1→ 2) Araf
residues (Seidel et al. 2007). C-5 of the terminal β-
D-Araf and the penultimate 2-α-D-Araf of this
motif act as anchoring points for mycolic acids
(McNeil et al. 1991).
The Emb arabinosyltransferases are inhibited by
EMB, a well-recognized anti-TB drug, which is
employed in the short-course treatment strategy of
TB. Eﬀorts are focused on investigating EMB analo-
gues, such as SQ109 (Jia et al. 2005a, b, c; Sacksteder
et al. 2012) and SQ775 (Bogatcheva et al. 2006), for
future lead drug development. Interestingly, the
other AraTs are not inhibited by EMB (Alderwick
et al. 2006; Seidel et al. 2007; Birch et al. 2008)
and screening for inhibitors against these enzymes
is hindered due to the nature of the protein and sub-
strate (membrane bound). However, there have been
reports on the development of DPA analogues for
the inhibition of arabinogalactan biosynthesis
(Pathak et al. 2001; Owen et al. 2007). A recent
study employing a cell free assay approach with
membrane preparations has determined that
various DPA analogues are able to limit the incorp-
oration of a radiolabelled DP[14C]A (Zhang et al.
2011).
The primary structure of arabinogalactan is
completed by the transfer of succinyl and D-GalN
residues to the inner arabinan units. PpgS, polypre-
nyl-phospho-N-acetylgalactosaminyl synthase, cat-
alyses the formation of polyprenol-P-D-GalNAc
from polyprenyl-P and UDP-GalNAc, which is
then translocated across the membrane (Skovierova
et al. 2010; Rana et al. 2012). The deacylation to
polyprenol-P-D-GalN occurs in an undetermined
location and by an unknown mechanism. The glyco-
syltransferase, Rv3779, transfers D-GalN to arabi-
nogalactan at the C-2 position of 3,5-branched
Araf residue (Scherman et al. 2009; Skovierova
et al. 2010; Peng et al. 2012; Rana et al. 2012).
Succinylated Araf residues have also been detected
at this position of non-mycolated arabinan chains
(Bhamidi et al. 2008), but the enzyme responsible
is currently unknown. A comprehensive mechanistic
and functional understanding of these enzymes is
required for evaluation as suitable drug targets and
to date, there are no identiﬁed inhibitors against
these processes. The ﬁnal stage is the attachment of
the arabinogalactan macromolecule to peptidogly-
can. The enzyme responsible for this essential liga-
tion has recently been elucidated to be Lcp1
(Harrison et al. 2016).
PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES ,
LIPOMANNAN AND LIPOARABINOMANNAN
The glycolipids, phosphatidyl-myo-inositol manno-
sides (PIMs), and the related lipoglycans, lipoman-
nan (LM) and lipoarabinomannan (LAM), are
non-covalently anchored into the inner and outer
6Katherine A. Abrahams and Gurdyal S. Besra
http://dx.doi.org/10.1017/S0031182016002377
Downloaded from https:/www.cambridge.org/core. University of Birmingham, on 10 Jan 2017 at 12:38:16, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
membranes of the cell wall via the phosphatidyl-
myo-inositol unit (Ortalo-Magne et al. 1996)
(Fig. 1). The core structure of PIM consists of an
acylated sn-glycerol-3-phospho-(1-D-myo-inositol),
the phosphatidyl inositol (PI) unit. Glycosylation
with mannopyranose (Manp) residues at the O-2
and O-6 positions of myo-inositol, results in the
mannosyl phosphate inositol (MPI) anchor (Ballou
et al. 1963; Ballou and Lee, 1964; Nigou et al.
2004). The MPI structure is highly diverse, with
variations in the type (commonly palmitic and
tuberculostearic chains (Pitarque et al. 2005)),
number and location of acyl chains. The most preva-
lent forms of PIMs in mycobacteria are tri- and
tetra-acylated phospho-myo-inositol di/hexamanno-
sides (Ac1PIM2, Ac1PIM6, Ac2PIM2, Ac2PIM6),
where in the hexamannosides, there is one Manp
unit on the O-2 and ﬁve Manp units on the O-6 pos-
ition of myo-inositol (Gilleron et al. 2001).
Extensions of mannan and arabinomannan chains
on the MPI anchor form LM and LAM, respect-
ively. In both LM and LAM, the mannan chain con-
sists of approximately 21–34 α(1→ 6) linked Manp
units, decorated with single α(1→ 2)-Manp residues
(Kaur et al. 2008). In LAM, the mannan chain is
glycosylated through an α(1→ 2) linkage with
∼50–80 Araf residues (Khoo et al. 1996).
In mycobacteria, PI and PIMs contribute up to
56% of all phospholipids in the cell wall and 37%
in the cytoplasmic membrane (Goren, 1984).
These signiﬁcant quantities indicate their import-
ance. Not only are they structural components,
they also have roles in cell wall integrity, permeabil-
ity and control of septation and division (Parish et al.
1997; Patterson et al. 2003; Fukuda et al. 2013). LM
and LAM are involved in Mtb pathogenicity, with
evidence to suggest they are modulators of host–
pathogen interactions (Schlesinger et al. 1994;
Nigou et al. 2002; Maeda et al. 2003). These features
of PIMs, LM and LAM make them suitable targets
in anti-TB drug discovery.
BIOSYNTHESIS OF PHOSPHATIDYL-
MYO-INOSITOL MANNOSIDES , LIPOMANNAN
AND LIPOARABINOMANNAN
PIM biosynthesis begins in the cytoplasm (Fig. 4).
The α-mannopyranosyl transferase (ManpT),
PimA, of the GT-A/B superfamily, transfers Manp
from the donor GDP-Manp to position O-2 of the
Fig. 4. Inhibitors targeting the biosynthesis of phosphatidyl-myo-inositol mannosides, lipomannan and
lipoarabinomannan. The current understanding of the biosynthesis of PIMs, LM, LAM and ManLAM. Reported
inhibitors are shown in red.
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myo-inositol ring to form PIM1 (Kordulakova et al.
2002; Guerin et al. 2007). A second Manp residue is
transferred to position O-6 of the myo-inositol ring
by PimB’ to form PIM2 (Guerin et al. 2009).
Acylation of the Manp residue of PIM1 is performed
by the acyltransferase Rv2611c before or after the
addition of the second Manp residue (Kordulakova
et al. 2003). The acylation of the C-3 position of the
myo-inositol ring is performed by an unknown acyl-
transferase. This ﬁnishes the synthesis of the MPI
anchor. Mannosylation of Ac1/Ac2PIM2 to Ac1/
Ac2PIM3 is performed by a ManpT, designated
PimC, but this enzyme is yet to be conﬁrmed in
Mtb H37Rv (Kremer et al. 2002b). It is suspected
that the subsequent addition of Manp to the non-
reducing end of Ac1/Ac2PIM3 is performed by the
unidentiﬁed PimC or PimD forming Ac1/Ac2PIM4.
The ManpTs have been the subject of target-based
screening programs. More speciﬁcally, in vitro
PimA activity was screened with approximately 350
compounds. Several hit molecules exhibited signiﬁ-
cant inhibition, but the compounds did not exhibit
in vivo activity in Mtb (Sipos et al. 2015). Substrate
analogues of PimA and PimB’, galactose-derived
phosphonate analogs of PI, have also been developed,
which show enzyme inhibition in a cell-free system
(Dinev et al. 2007).
The biosynthesis of Ac1/Ac2PIM4 marks the tran-
sition towards the synthesis of higher order PIMs,
LM and LAM (Fig. 4). It is predicted that the syn-
thesis of Ac1/Ac2PIM4 occurs on the cytoplasmic
side of the membrane, and at this point, is ﬂipped
across the membrane by an unidentiﬁed translocase,
with the remainder of the steps thought to occur in
the periplasmic space. The integral membrane
ManpTs (of the GT-C glycosyltransferase super-
family) are reliant on polyprenyl-phosphate-based
mannose donors (PPM) rather than the nucleotide-
based sugars (Berg et al. 2007). The polyprenol
monophosphomannose synthase, Ppm1, catalyses
the synthesis of PPM from GDP-Manp and poly-
prenol phosphates (Gurcha et al. 2002).
PimE catalyses the transfer of an α(1→ 2)-linked
Manp residue onto Ac1/Ac2PIM4, generating Ac1/
Ac2PIM5 (Morita et al. 2006). The transfer of the
last Manp residue is either performed by PimE or
by an unidentiﬁed GT-C glycosyltransferase
forming Ac1/Ac2PIM6 (Morita et al. 2006). The
distal 2-linked Manp residues are not present in
the mannan core of LM or LAM; Ac1/Ac2PIM4 is
the likely precursor for the extension of the
mannan chain. Recent evidence suggests that the
putative lipoprotein LpqW channels intermediates
such as Ac1/Ac2PIM4 towards either PimE (to
form the polar lipids) or to LM and LAM synthesis
(Crellin et al. 2008). The mannosyltransferases,
MptA and MptB (Mishra et al. 2007, 2008), are
responsible for the α(1→ 6)-linked mannan core of
LM and LAM. MptC catalyses the transfer of the
monomannose side chains via α(1→ 2) linkages,
forming mature LM (Kaur et al. 2008; Mishra
et al. 2011). Modiﬁcation of LM leads to LAM.
Approximately 50–80 Araf residues are added
using DPA as the donor, comparable to that of the
arabinogalactan domain. An unidentiﬁed ArafT
primes the mannan chain, which is further elongated
by EmbC, adding 12–16 Araf residues with α(1→ 5)
linkages (Shi et al. 2006; Alderwick et al. 2011a).
AftC, the same enzyme involved in arabinogalactan
synthesis, integrates α(1→ 3) Araf branches (Birch
et al. 2008). It has also been speculated that AftD
introduces α(1→ 3) Araf, but its function is yet to
be conﬁrmed (Skovierova et al. 2009). The arabinan
domain is terminated by β(1→ 2) Araf linkages, pre-
dicted to be performed by AftB, resulting in
branched hexa-arabinoside or linear tetra-arabino-
side motifs. Further structural heterogeneity is
introduced by capping motifs. These moieties
consist of a number of α(1→ 2)-linked Manp resi-
dues, producing mannosylated LAM (ManLAM)
(Kaur et al. 2008). Using PPM, the α(1→ 5)
ManpT, CapA, attaches the ﬁrst Manp residue
(Dinadayala et al. 2006). MptC catalyses the add-
ition of subsequent α(1→ 2) Manp residues
(Kaur et al. 2008), which can be decorated with an
α(1→ 4)-linked 5-deoxy-5-methyl-thio-xylofuranose
(MTX) residue (Ludwiczak et al. 2002; Turnbull
et al. 2004). The enzymes involved in the addition
of MTX and succinyl residues to LAM are still to
be determined.
The essentiality of PPM in lipoglycan biosyn-
thesis makes Ppm1 an attractive drug target.
Amphomycin, a lipopeptide antibiotic, inhibits the
synthesis of PPM by sequestering the polyprenol
phosphates, and consequently inhibits the extracel-
lular ManpTs (Banerjee et al. 1981; Besra et al.
1997). Guy et al. (2004) designed a variety of
prenyl-based photoactivable probes. Upon photoac-
tivation, a number of the probes exhibited inhibitory
activity against Mtb Ppm1 and M. smegmatis
α(1→ 6) ManpTs (Guy et al. 2004). Substrate
analogues of the ManpTs have been designed to
investigate enzyme–substrate interactions and
mechanisms of action (Brown et al. 2001; Tam and
Lowary, 2010). These types of studies will provide
an invaluable insight into the interactions involved
and for the future design of inhibitors.
MYCOLIC ACIDS
The ﬁnal distinctive component of the mycobacter-
ial cell wall is the unique fatty acids, termed the
mycolic acids (Fig. 1). These unique long chain α-
alkyl-β-hydroxy fatty acids (comprised a meromyco-
late chain of C42–C62 and a long saturated α-chain
C24–C26) are attached to the arabinogalactan layer,
but also make up other outer cell envelope lipids
such as trehalose mono/di-mycolates and glucose
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monomycolate. There are three subclasses of
mycolic acids: α-mycolates, containing cyclopropane
rings in the cis-conﬁguration; methoxy-mycolates
and keto-mycolates containing methoxy or ketone
groups, respectively, and have cyclopropane rings
in the cis- or trans- conﬁguration (Brennan and
Nikaido, 1995; Watanabe et al. 2001, 2002).
Mycolic acids contribute to the permeability of the
cell wall, and as such are essential for cell viability,
and are also essential in virulence, making the bio-
synthesis of mycolates suitable drug targets (Liu
et al. 1996).
MYCOLIC ACID BIOSYNTHESIS
Mycolic acid biosynthesis occurs in the cytoplasm,
involving two distinct pathways, termed fatty acid
synthase types I and II (FAS I and FAS II)
(Fig. 5). FAS I (Rv2524c), a multifunctional poly-
peptide, generates short-chain fatty acyl-CoA
esters that can either form the saturated α-branch
(C24), or be extended by FAS II to form the mero-
mycolate chain (Cole et al. 1998). Elongation of the
fatty acids is dependent on the availability of holo-
AcpM, an acyl carrier protein, and malonyl-CoA.
FabD, the malonyl:AcpM transacylase generates
malonyl-AcpM (Kremer et al. 2001b). C14-CoA
primers from FAS I are condensed with malonyl-
AcpM, catalysed by FabH (β-ketoacyl ACP
synthase) (Choi et al. 2000), forming a pivotal link
between the FAS I and FAS II pathways. The
C16-AcpM formed is channeled to the FAS II
pathway (Bhatt et al. 2007), where it undergoes a
round of keto-reduction, dehydration and enoyl-
reduction, catalysed by: MabA, a β-ketoacyl-AcpM
reductase (Marrakchi et al. 2002); HadAB/BC, a β-
hydroxyacyl-AcpM hydratase (Sacco et al. 2007);
InhA, an enoyl-AcpM reductase (Banerjee et al.
1994). Successive cycles ensue, whereby the conden-
sation reaction of FabH is replaced by the activities
of KasA and KasB, β-ketoacyl synthases (Schaeﬀer
et al. 2001; Kremer et al. 2002a). The AcpM-
bound acyl chain extends by two carbon units in
each cycle, forming a saturated long-chain meromy-
colate of C42–C62, which is subject to modiﬁcations
such as cis-/trans-cyclopropanation, and the addition
of methoxy and keto groups (Dubnau et al. 2000;
Glickman et al. 2000; Glickman, 2003; Barkan
et al. 2010). FabD32, a fatty acyl-AMP ligase, acti-
vates the meromycolate chain (Trivedi et al. 2004)
and the subsequent meromycolyl-AMP is linked
with the α-alkyl-CoA ester, catalysed by Pks13, to
generate a α-alkyl-β-keto-mycolic acid (Gande
et al. 2004; Portevin et al. 2004). Finally a reduction
step, catalysed by Rv2509, generates a mature myco-
late (Bhatt et al. 2008). Transport of the mycolates to
either the cell envelope or for attachment to arabino-
galactan remains to be elucidated. It is considered that
Fig. 5. Inhibitors targeting mycolic acid biosynthesis. The enzymes involved in the mycolic acid biosynthetic pathway are
presented. Reported inhibitors are shown in red. ‘R’ represents an acyl chain of varying carbon units in length.
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the mycolates are transported in the form of trehalose
monomycolate (TMM). In the generation of TMM,
Takayama et al. (2005) propose that a mycolyl-
transferase transfers the mycolyl group from
mycolyl-Pks13 to D-mannopyranosyl-1-phospho-
heptaprenol (Besra et al. 1994). The mycolyl group
of mycolyl-D-mannopyranosyl-1-phosphoheptapre-
nol is transferred to trehalose-6-phosphate by a
second mycolyltransferase, forming TMM-phos-
phate. The phosphate moiety is removed by a trehal-
ose-6-phosphate phosphatase, and the TMM is
immediately translocated outside of the cell using a
resistance-nodulation-division (RND) family of
eﬄux pumps, termed mycobacterial membrane
proteins large (MmpL), limiting TMM accu-
mulation in the cytoplasm (Takayama et al. 2005;
Grzegorzewicz et al. 2012; Varela et al. 2012).
Finally, the mycolyltransferase Antigen 85 complex,
formed of Ag85A, Ag85B and Ag85C, attaches the
mycolic acid moiety from TMM to arabinogalactan
(Jackson et al. 1999). This complex also catalyses
the formation of trehalose dimycolate, TDM, from
two TMM molecules with the release of trehalose
(Takayama et al. 2005). TDM, or ‘cord factor’, is
implicated in the pathogenicity ofMtb.
The enzymes involved in mycolic acid biosyn-
thesis are the targets of numerous inhibitors. In
1952, shortly after its discovery, isoniazid (INH)
was administered as a front-line and essential anti-
biotic in the treatment of TB (Medical Research
Council, 1952) and has only recently had the mode
of action elucidated. Initially thought to target
KatG due to mutations in the corresponding gene
in resistant isolates (Zhang and Young, 1994;
Rouse and Morris, 1995), INH was later revealed
to be a pro-drug, with the true target being InhA
(Banerjee et al. 1994; Larsen et al. 2002).
Ethionamide, a structural analogue of INH, also
requires cellular activation via EthA, before target-
ing InhA (Banerjee et al. 1994). Direct inhibitors
of InhA that do not require activation are now
being searched for (Lu et al. 2010; Vilcheze et al.
2011; Pan and Tonge, 2012; Encinas et al. 2014;
Manjunatha et al. 2015; Sink et al. 2015; Martinez-
Hoyos et al. 2016). One such molecule is the
broad-spectrum antibiotic triclosan, which has not
been adopted in TB treatment due to its sub-
optimal bioavailability (Wang et al. 2004). In the
last year, GlaxoSmithKline have published a set of
thiadiazole compounds, which directly target
InhA, with GSK693 demonstrating in vivo eﬃcacy
comparable to INH (Martinez-Hoyos et al. 2016).
Therefore, old drug targets should not be discounted
in the search for new anti-tubercular agents.
The β-ketoacyl synthases, KasA and KasB, are the
targets of the natural products cerulenin (Parrish et al.
1999; Schaeﬀer et al. 2001; Kremer et al. 2002a), pla-
tensimycin (Brown et al. 2009), and thiolactomycin
(TLM) (Kremer et al. 2000; Schaeﬀer et al. 2001).
There has been signiﬁcant interest in TLM due to
its broad-spectrum activity and numerous analogues
have been synthesized to improve on potency and
pharmacokinetic properties (Kremer et al. 2000;
Senior et al. 2003, 2004; Kim et al. 2006). The
biphenyl-based 5-substituents of TLM also exhibit
in vitro activity against FabH, but with no whole-
cell activity (Senior et al. 2003, 2004). The 2-tosyl-
naphthalene-1,4-diol pharmacophore of TLM also
has in vitro activity against FabH, however, whole-
cell data are yet to be published (Alhamadsheh et al.
2008). Recently, a new anti-TB compound, an inda-
zole sulfonamide GSK3011724A, was discovered
from a phenotypic whole-cell HTS (Abrahams et al.
2016). The compound was shown to target KasA spe-
ciﬁcally, with no discernable target engagement with
KasB or FabH, and is currently the focus of medi-
cinal chemistry optimization (Abrahams et al. 2016).
Due to the success of InhA as a chemotherapeutic
target, there is a mounting interest in the other
enzymes involved in mycolic acid biosynthesis from
a drug target perspective that could bypass INH
resistance in MDR and XDR-TB. Formerly used in
the treatment of TB, the thiocarbamide-containing
drugs, thiacetazone and isoxyl, were shown to target
mycolic acid biosynthesis and the inhibition mechan-
ism has recently been elucidated. Following activation
by EthA, both drugs target the HadA subunit of the
HadABC dehydratase, forming a covalent interaction
with the active site cysteine (Grzegorzewicz et al.
2015). It has also been shown that thiacetazone inhi-
bits cyclopropanation of mycolic acids (Alahari et al.
2007). MabA has been the subject of a molecular
docking study. Comparable with the control inhibi-
tory substrate isonicotinic-acyl-NADH, pteleoellagic
acid had a high docking score with in vivo activity to
be conﬁrmed (Shilpi et al. 2015). Through a target-
based screening approach linked with whole-genome
sequencing of resistant mutants, a benzofuran has
been shown to target Pks13 (Ioerger et al. 2013).
Additionally, Pks13 is the target of thiophene
compounds (Wilson et al. 2013) including 2-
aminothiophenes (Thanna et al. 2016). From a GFP
reporter-based whole-cell HTS, a diarylcoumarin
exhibited potent activity against Mtb and this struc-
tural class was shown to target FadD32 by inhibiting
the acyl–acyl carrier protein synthetase activity
(Stanley et al. 2013). The homologue of the Rv2509
reductase in M. smegmatis is non-essential but loss of
function increases susceptibility to lipophilic antibio-
tics such as rifampicin. Targeting this ‘secondary’
drug target in Mtb could increase the susceptibility
of the bacilli to antibiotics (Bhatt et al. 2008). The
Antigen 85 complex has been the focus of a number
of inhibitor-based screening studies (Belisle et al.
1997; Gobec et al. 2004; Sanki et al. 2008, 2009;
Elamin et al. 2009; Barry et al. 2011). Recently, an
inhibitor from a compound library was shown to
bind toAntigen 85C, and derivatives of this compound
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have been synthesized, with 2-amino-6-propyl-
4,5,6,7-tetrahydro-1-benzothiphene-3-carbonitrile
(I3-AG85) exhibiting the lowest MIC in Mtb and
drug-resistant strains (Warrier et al. 2012).
In the target identiﬁcation of new anti-tubercular
compounds, some targets can be regarded as promis-
cuous, inhibited by multiple diﬀerent chemical
scaﬀolds, exempliﬁed by MmpL3 (Grzegorzewicz
et al. 2012; La Rosa et al. 2012; Stanley et al. 2012;
Tahlan et al. 2012; Lun et al. 2013; Remuinan
et al. 2013), a predicted TMM transporter.
Through the generation and sequencing of spontan-
eous resistant mutants, a number of inhibitors with
diverse chemical structures have been shown to
target MmpL3 (Grzegorzewicz et al. 2012; La
Rosa et al. 2012; Stanley et al. 2012; Tahlan et al.
2012; Lun et al. 2013; Remuinan et al. 2013).
However, a recent chemoproteomics approach
determined that one of the proposed inhibitor
classes of MmpL3, the tetrahydropyrazo[1,5-a]pyr-
imidine-3-carboxamides (THPPs), has a novel alter-
native target, EchA6 (Cox et al. 2016). Sequence
analysis predicted EchA6 to be an enoyl-CoA hydra-
tase, but it lacks the residues required for catalytic
activity. Through an extensive biochemical investi-
gation, Cox et al. (2016) predicted that EchA6 shut-
tles fatty acyl-CoA esters from the β-oxidation
pathway into FAS II, ready for the condensation
activities of KasA or KasB with malonyl-AcpM.
This research demonstrates that target identiﬁcation
of inhibitory compounds can unveil not only a new
biological pathway, but also an untapped area for
drug targets.
DRUG DISCOVERY EFFORTS
The strategies involved in drug discovery are forever
evolving. Traditional enzyme screening campaigns
and medicinal chemistry focused on ligand-based
inhibitor designs (such as substrate or transition
state analogues) that once dominated drug discovery
are being superseded by phenotypic HTS. The
former approach often relies on the X-ray crystal
structure of the enzyme or biochemical understand-
ing, and successful inhibitors from these screens are
further challenged by target engagement in vivo.
Over recent years, HTS has become the lead
approach in drug discovery. HTS employs extensive
compound libraries of diverse chemical structures,
and as a consequence, these methods can identify a
multitude of inhibitors with novel chemical
scaﬀolds. Phenotypic HTS can reveal anti-TB
agents with whole-cell activity and unknown
modes of action, having the potential to unveil new
biochemical pathways (Abrahams et al. 2012, 2016;
Gurcha et al. 2014; Mugumbate et al. 2015).
Alternatively, phenotypic HTS can be target-
based, focusing on enzymes or pathways such as
those involved in cell wall biosynthesis. This can
be a very eﬀective way to identify novel anti-TB
compounds with known modes of action, but is
limited by the speciﬁed target (Batt et al. 2015;
Martinez-Hoyos et al. 2016). Target assignment is
a fundamental step in in the drug discovery pipeline.
Without knowledge of the physiological target,
eﬀorts can be wasted on developing compounds
against an unsuitable target, such as those homolo-
gous in humans. Establishing the mode of action of
an inhibitor is a prerequisite for facilitating medi-
cinal chemistry eﬀorts to convert compounds into
potential drug candidates.
Concluding remarks
The essential mycobacterial cell wall, responsible for
structural integrity, permeability and pathogenicity,
is an attractive drug target, both structurally and bio-
synthetically. Recent advancements in biochemical
and omics-based techniques have led to the discovery
and mechanistic understanding of enzymes involved
in mycobacterial cell wall synthesis and assembly.
Although a number of key enzymes are yet to be
established, there are a plethora of suitable targets,
exploited not only in current treatment programmes
but also for anti-TB drug discovery. In the current
TB treatment regimen, two of the front-line drugs,
INH and EMB, target mycolic acid and arabinogalac-
tan biosynthesis, respectively, with the second-line
drugs such as ethionamide andD-cycloserine also tar-
geting cell wall production. The proven success of
these drugs validates the future development of inhi-
bitors targeting the unique mycobacterial cell wall,
which remains a source of unexploited clinically rele-
vant drug targets. The continued progression in drug
discovery approaches and the optimization of bio-
chemical techniques, will enable the rapid identiﬁca-
tion of anti-TB agents, many of which are likely to
target the biosynthesis of the so-called ‘Achilles
heel’ ofMtb.
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